These proteins share a highly homologous Jumonji C domain endowed with Fe2+ and α‐ketoglutarate for the demethylation of H3K27.1 Overexpression of JMJD3 is correlated with inflammation,2, 3 neurological disorders,4 as well as cancer pathologies5 such as T‐cell acute lymphoblastic leukemia,6 Hodgkin's lymphoma,7 and metastatic prostate cancer.8 It has also been recently shown that JMJD3 can be a new target for pediatric brainstem glioma.9 Because JMJD3 is an inducible enzyme, its suppression could be very attractive for cancer treatment. This evidence concerns the gene KDM6B and cancer.